**Bedside assessment of quadriceps muscle using ultrasound following admission for acute exacerbations of chronic respiratory disease**

Neil J. Greening1,2, Theresa C. Harvey-Dunstan1, Emma J. Chaplin1, Emma E. Vincent1,2, Mike D. Morgan1, Sally J. Singh1,2,3, Michael C. Steiner1,3

Affiliations

1Centre for Exercise and Rehabilitation Science, Institute of Lung Health, Leicester Respiratory Biomedical Research Unit, Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK

2Department of Infection, Inflammation and Immunity, University of Leicester, Leicester, UK

3School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK

Corresponding author

Dr Neil Greening, Institute of Lung Health, Leicester Respiratory Biomedical Research Unit, Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK. Email: njg27@le.ac.uk

Author contributions

NG, TH-D, SS and MS conceived the study. NG, TH-D, EC, and EV recruited patients and conducted the study. Data analysis was performed by NG, MM, SS and MS. All authors contributed to the writing of the paper.

Funding

The research was funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care in Leicestershire, Northamptonshire and Rutland (CLAHRC LNR). Support was also provided by the NIHR Leicester Respiratory Biomedical Research Unit.

Running Head: Ultrasound measurement of quadriceps following acute exacerbation of chronic respiratory disease

Subject Category: 9.8 COPD: Functional Assessment (Exercise)

Word Count: 2,628

At a Glance Commentary

Scientific Knowledge on the Subject

Hospitalisation, and subsequent readmission, for exacerbations of chronic respiratory diseases are associated with worse health status and higher risk of death. Systemic effects, such as skeletal muscle dysfunction, are known to be of prognostic importance in the stable state, but its effects during severe exacerbations on long-term outcome are unknown.

What this Study Adds to the Field

Skeletal muscle dysfunction, measured using ultrasound, is an independent risk factor for hospital readmission. Patients with smaller quadriceps are more likely to be readmitted to hospital.

**Abstract**

**Rationale:** Hospitalisation represents a major event in patients with chronic respiratory disease with high risk of readmission, which over the longer term may be related more closely to the underlying condition of the patient, such as skeletal muscle dysfunction.

**Objectives:** We assessed the risk of hospital readmission at one year, including measures of lower limb muscle as part of a larger clinical trial.

**Methods:** Patients hospitalised with an exacerbation of chronic respiratory disease underwent measures of muscle function including quadriceps ultrasound. Independent factors influencing time to hospital readmission or death were identified. Patients were classified into four quartiles based on quadriceps size and compared.

**Results:** 191 patients (mean age 71.6 [SD 9.1] years) were recruited. 130 (68%) were either readmitted or died. Factors associated with readmission or death were age (odds ratio 1.05, 95% CI 1.01-1.08; p=0.015), MRC dyspnoea grade (4.57, 2.62-7.95; p<0.001), home oxygen use (12.4 4.53-33.77; p<0.001), quadriceps cross sectional area (Qcsa) (0.34, 0.17-0.65, p=0.001) and hospitalisation in the previous year (4.82, 2.42-9.58; p<0.001). In the multivariate analyses, home oxygen use (4.80, 1.68-13.69; p=0.003), MRC dyspnoea grade (2.57, 1.44-4.59, p=0.001), Qcsa (0.46, 0.22-0.95; p=0.035) and previous hospitalisation (3.04, 1.47-6.29; p=0.003) were independently associated with readmission or death. Patients with the smallest muscle spent more days in hospital than those with largest muscle (28.1 (SD 33.9) days versus 12.2 (SD 23.5) days; p=0.007).

**Conclusions**: Quadriceps muscle measured using ultrasound in the acute care setting is an independent risk factor for unscheduled readmission or death, which may have value both in clinical practice and for risk stratification.

**Abstract Word Count**: 257

**MeSH terms:**

1. Pulmonary Disease, Chronic Obstructive
2. Muscle, Skeletal
3. Ultrasonography
4. Risk factors
5. Frail Elderly

**Introduction**

Hospitalisation for exacerbations of Chronic Obstructive Pulmonary Disease (COPD) and other Chronic Respiratory Diseases (CRD) are associated with worse health status and higher risk of death and subsequent readmission[1 2]. Measurements obtained during routine clinical care during hospitalisation can predict short term outcomes (for example in-hospital mortality and length of hospital stay)[3] but identifying those at risk of readmission over the longer term has proved more challenging. In the stable COPD population, previous exacerbations were the single most powerful predictor of subsequent events[4].

The risk of subsequent events following hospitalisation over the longer term may be related more closely to the underlying condition of the patient, including known systemic features of the disease such as skeletal muscle function. Previous studies have indicated that assessments of skeletal muscle function and mass predict mortality and symptom burden in the stable state independently from the severity and character of lung function impairment[5 6]. However, the predictive value of these indices in patients who have been hospitalised for an acute exacerbation (the population most at risk of adverse outcomes) is unknown. This is in part because technologies for assessing muscle function and mass that could be utilised at the bedside in acutely unwell subjects were not available. Simple measurements of muscle strength can be performed at the bedside but may be limited in this setting by their reliance on patient effort. Recent studies have suggested that ultrasound assessment of rectus femoris cross-sectional area (Qcsa) is a surrogate for lower limb muscle mass which can be performed at the bedside and is independent of patient effort[7-9].

We hypothesised that measurements of lower limb muscle function (mass and strength) and functional exercise capacity performed during acute exacerbation of chronic respiratory disease would be a risk factor for hospital re-admission in the subsequent 12 months. This was investigated prospectively by recording these assessments in a cohort of patients recruited within 48 hours of acute hospital admission to a clinical trial of early rehabilitation where 12 month readmission rate was the primary outcome. In this study no difference was seen in hospitalisation rate, though a higher mortality rate was seen in those in which those that received early rehabilitation compared to usual care[10].

**Methods**

Study design and population

Subjects were recruited to a randomised controlled trial of an early rehabilitation intervention initiated during hospitalisation for acute exacerbation of chronic respiratory disease. The outcome of the trial including recruitment, inclusion and exclusion criteria have previously been described[10]. This was an observational analysis of a subgroup of participants recruited at one of the study centres (Glenfield Hospital, Leicester, UK) where ultrasound assessments of muscle mass were made. Eligibility for the current study was defined by the performance of Qcsa prior to randomisation. Because the study intervention had no effect on hospital readmission or functional performance (see[10]), the treatment and control groups were combined for this analysis. Ethical approval for the study was given by the National Research Ethics Service, Nottingham REC 1 committee (09/H0403/76) and the study was registered on the ISRCTN (N05557928).

Outcome measures

Outcome measures were performed at recruitment (within 48 hours of acute admission) apart from spirometry and shuttle walk tests which were performed at hospital discharge because subjects were too unwell to perform them. Demographics, including MRC dyspnoea grade when at stable state (range 1-5), maximal isometric quadriceps strength (QMVC), measured using an isometric dynamometer[11], St George’s Respiratory Questionnaire (SGRQ)[12]and rectus femoris cross sectional area were (Qcsa) taken at time of recruitment. Spirometry, measured to BTS/ARTP standards[13], functional exercise performance, measured using the incremental shuttle walk test (ISWT)[14] and endurance shuttle walk tests (ESWT)[15], were performed at discharge. Previous hospitalisation over the previous 12 months was identified from hospital and General Practice records and patient recollection.

Rectus femoris cross sectional area (Qcsa)

Qcsa was measured using B mode ultrasonography (Hitachi). Images were captured using a 7.5 MHz 7cm linear probe. Rectus femoris of the right leg was used as a single muscle of the quadriceps as to allow whole muscle on a single image. Images were taken using the mid-distance between the greater trochanter and knee joint. This distance was measured on the anterior aspect of the thigh from the superior patellar border. The transducer was placed perpendicular to the leg, with minimal pressure to provide an adequate view in order to minimise muscle compression. Oblique images were minimised by placing the transducer perpendicular to the muscle and ensuring minimal cross sectional area on the image. Images were frozen and the outline of the rectus femoris traced to obtain cross sectional area measurement. Qcsa was taken as the mean of three consecutive measurements within 10% from separate frozen images. In order to adjust for the size of the individual Qcsa was standardised to height squared.

Hospitalisation and admission data

The primary outcome of the study was hospital readmission at 12 months, which was collected from local hospital databases and GP records. Date of admission, and length of hospital stay were recorded at 12 months. Death was identified from hospital databases, GP records, and death certificates at 12 months.

Statistical analysis

A composite endpoint of either hospitalisation or death in the follow up year was used as the primary outcome measure in this study. Statistical analysis was conducted using STATA SE version 13 (Statacorp, USA)). Factors associated with hospitalisation were identified by univariate model by logistic regression. Factors tested were any baseline characteristic or outcome measure tested during the index admission. Multivariate analyses with the selected factors identified from the univariate analysis were conducted with binary logistic regression using a backward stepwise approach, offset by exposure time. All analyses used the treatment allocation as a co-variate. Quadriceps mass, corrected by height squared, was divided into quartiles and the groups compared. Time to hospitalisation or death were compared using Cox regression. Total number of hospital days were compared using Kruskal-Wallis. Finally the clinical characteristics of the different groups identified were compared using independent ANOVA and Kruskal-Wallis for parametric and non-parametric continuous data as appropriate. Categorical measures were compared using chi-squared.

**Results**

Baseline characteristics and readmission

A total of 191 subjects underwent ultrasound of the Qcsa at baseline and were included in the analysis. This represented 96% of those enrolled at the Glenfield site in the original clinical trial (n=200). Baseline characteristics and measures are shown in table 1. 130 (68%) of the subjects were either readmitted or died in the year following their index admission, of which 121 were admitted and 9 died without readmission. Mean time to readmission or death was 120 (95% CI 101-139) days. Test-retest correlation between left and right Qcsa was 0.92 and ICC Cronbach’s alpha = 0.95, which is similar to previous data[7 16].

Factors associated with time to hospitalisation or death

In the univariate logistic regression analysis of all available in-hospital assessments, the risk of either hospitalisation or death was calculated. Factors significantly associated with readmission were MRC grade, home oxygen use, quadriceps cross sectional area and previous hospitalisation and age (table 2).

Significant factors from the univariate analysis were entered into a multivariate model using a backward stepwise approach. Factors associated independently with further hospitalisation were MRC grade, quadriceps cross-sectional area, previous hospitalisation and home oxygen. Age was not significantly associated (p=0.272). Odds ratios are shown in table 3.

Clinical characteristics of Patients of Different Quadriceps Mass

Participants were grouped into quartiles based on their quadriceps mass (quartile 1 range 0.816-1.407 cm2/m2, quartile 2 range 1.408-1.722 cm2/m2, quartile 3 range1.731-2.053 cm2/m2, quartile 4 range 2.059-3.500 cm2/m2) Baseline characteristics and demographics were compared between the groups (table 4). Subjects with a smaller Qcsa were more likely have a lower BMI and weight, and be weaker. There was a trend to worse FEV1 in the smaller muscle groups and a longer index length of hospital stay.

Risk of Hospitalisation

In the year following the index admission the mean number of admissions were; quartile one (smallest muscle) 2.5 (95% CI 1.4-3.2), quartile two 1.3 (95% CI 0.8- 1.7), quartile three 1.5 (95% CI 1.0-2.0) and quartile four (largest muscle) 1.7 (95% CI 1.0-2.4) (p=0.025). Risk of hospitalisation using Cox regression was significantly higher in the smallest muscle group compared to largest (HR 1.99, 95% CI 1.21-3.27, p=0.007) (figure 1).

Number of Hospital Days

The number of hospital days in the year following the original admission was significantly higher in the smallest muscle group (p=0.007) with 28.1 (SD 33.9) days per subject in quartile one, 11.9 (SD19.0) in quartile two, 12.9 (SD 23.1) in quartile three and 12.2 (SD 23.5) in the largest muscle group (quartile four) (figure 2).

Mortality

13 (28%) of the smallest muscle group (quartile one) died compared with 10 (21%) of quartile two, 7 (15%) of quartile three and 5 (10%) of the largest muscle group (quartile four) with no difference between groups at 12 months (p=0.145). No difference in mortality was seen when correcting for MRC dyspnoea grade, previous hospitalisation, home oxygen and treatment allocation using cox regression (Smallest [reference variable] versus largest muscle groups, HR 0.43, 95% CI 0.15-1.21, p=0.110).

Mortality in the different quartiles were compared between the intervention and usual care groups to test if the excess mortality observed in the intervention group in the original trial was in a specific quadriceps size. The difference in mortality between intervention and usual care groups was similar in all quadriceps sub groups (see Table S1 in supplement, p=0.404).

**Discussion**

In this study we demonstrate that indices of muscle function measured early during hospitalisation influence the risk of re-admission over the subsequent 12 months. Qcsa but not muscle strength was independently associated with hospital re-admission or death and in a multivariate model this association remained significant alongside MRC dyspnoea grade, home oxygen use, and hospitalisation in the previous 12 months. Other measures of functional exercise performance (field walking performance) were also not significantly associated with readmission or death when measured at time of discharge from hospital. Muscle strength can also be performed during the acute illness but did not significantly influence readmission rate possibly because the volitional component of the assessment of strength was affected by the acute illness.

Qcsa measurement was used as a marker of muscle mass in the current study. This technique has been previously validated against CT measurements of quadriceps CSA [7] and DEXA[9] in COPD populations and has practical utility in the acute setting because it is independent of patient effort and can be performed at the bedside. Qcsa has previously been shown to be related to quadriceps strength and physical activity in stable COPD[17 18], and more recently been used to demonstrate progressive wasting in the intensive care environment[8]. It is likely to offer a more sensitive and reliable measure of muscle mass than other potential bedside measures such as bio-electrical impendence analysis which may not be able to detect regional loss of muscle mass and is subject to variation due to shifts in hydration status which will be more important during the acute illness.

The impact of an exacerbation of respiratory disease on an individual will be determined by a combination of the severity of the acute event and the pre-morbid condition of the patient. As expected, our data confirm that measures of the physical condition of the patient can predict longer term re-admission risk but importantly indicate that non-volitional measures such as US remain discriminatory for this long term outcome even when performed during the acute event. This contrasts with volitional measurements such as muscle strength or walking performance which were not predictive when performed in this setting presumably because they were influenced by the acuity of the event.

Subjects in the smallest muscle group were more likely to be re-admitted or die (as expected) but also had more days in hospital over the subsequent 12 months. The small muscle group was characterised by muscle strength, with a trend to worse lung function and increased mobility limiting co-morbidities, which might explain the differences in re-admission rate although these factors were not significant in the multivariate regression analysis. It is possible that reduced Qcsa is a surrogate for general “frailty” in this population. Objective measurements of frailty (for example 4m gait speed) may also be of discriminatory value in predicting re-hospitalisation.[19].

We observed a higher proportion in the mean number of hospital days between the smallest and largest muscle groups, compared to number of hospital admissions. This suggests that skeletal muscle dysfunction is not only important for admission to hospital but also the severity and duration of the admission. Better physical condition, represented by larger muscle mass, may allow patients who have been admitted to hospital to be better able to cope with the insult of a severe illness and hospitalisation[20 21], resulting in a shorter length of stay. Interventions to support this concept include Griffiths et al, who observed a decrease in hospital days, but no reduction in hospital admissions following pulmonary rehabilitation[22].

There was no statistical difference in mortality between the smallest muscle and largest muscle groups, though the absolute difference was 18% in favour of the largest muscle group. It is likely that this study was underpowered for this measure and further research would be of benefit, as other studies have suggested that reduced muscle function (mass and strength) is an independent predictor of mortality in COPD[5].

This is the first study to report the predictive value of measurements of muscle function taken during hospitalisation for exacerbations of chronic respiratory disease. Our data is in line with other studies suggesting that self-reported physical activity after discharge[23] and its recovery at one month predict the risk of re-admission[24].

Our study suggests that measures of muscle function can be recorded during hospital admission and may provide an opportunity for future risk stratification. The identification of such risk strata is of considerable interest because of the burden and cost of unscheduled hospitalisation to patients and health care systems and may inform treatment decisions (for example prioritisation of palliative or end of life care) or identify populations suitable for targeted interventions.

The original clinical trial for this study showed no difference in hospitalisation rate between an early rehabilitation intervention and usual care, though an increase in mortality was seen in the intervention group. These data demonstrate, based on quadriceps size, no difference in mortality or efficacy of the intervention in any particular subgroup. It is unknown whether other interventions, such as post exacerbation pulmonary rehabilitation or other targeted therapies would be more effective or more acceptable in patients with a better prognosis (i.e. those with larger muscle)[25-27].

Limitations to the analysis described in this study are acknowledged. Although the data was collected prospectively, it is a secondary, subgroup analysis of a clinical trial and risk stratification was not the purpose of the investigation. In any multivariate analysis, limitations are posed by the range of measures that are available. Qcsa using ultrasound is not a routinely measure. However, it is a simple measure to perform and bedside ultrasound equipment is already routinely available in the acute care setting for other indications, such as the investigation of pleural disease. We used the ISWT and ESWT as measures of maximal and sub-maximal exercise capacity. It is possible that other measures such as the 6 minute walk test (6MWT) may have been of prognostic use. However, both the ISWT and ESWT are well validated[28] and the ESWT and 6MWT have similar exercise response profiles[29], though there has been limited data for any of these tests in the acute hospital setting.

In conclusion, bedside assessment of lower limb muscle mass in the acute care setting is a risk factor for subsequent unscheduled admission to hospital for exacerbations of chronic respiratory disease. Such measurements may have value in both in clinical practice and as a risk stratification tool in these populations.

**References**

1. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;**57**(10):847-52

2. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 1998;**157**(5 Pt 1):1418-22 doi: 10.1164/ajrccm.157.5.9709032[published Online First: Epub Date]|.

3. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012;**67**(11):970-6 doi: 10.1136/thoraxjnl-2012-202103[published Online First: Epub Date]|.

4. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. The New England journal of medicine 2010;**363**(12):1128-38 doi: 10.1056/NEJMoa0909883[published Online First: Epub Date]|.

5. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007;**62**(2):115-20 doi: 10.1136/thx.2006.062026[published Online First: Epub Date]|.

6. Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. The European respiratory journal 1997;**10**(2):417-23

7. Seymour JM, Ward K, Sidhu PS, et al. Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. Thorax 2009;**64**(5):418-23 doi: 10.1136/thx.2008.103986[published Online First: Epub Date]|.

8. Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA : the journal of the American Medical Association 2013;**310**(15):1591-600 doi: 10.1001/jama.2013.278481[published Online First: Epub Date]|.

9. Menon MK, Houchen L, Harrison S, et al. Ultrasound assessment of lower limb muscle mass in response to resistance training in COPD. Respiratory research 2012;**13**:119 doi: 10.1186/1465-9921-13-119[published Online First: Epub Date]|.

10. Greening NJ, Williams JE, Hussain SF, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. Bmj 2014;**349**:g4315 doi: 10.1136/bmj.g4315[published Online First: Epub Date]|.

11. Edwards RH, Hyde S. Methods of measuring muscle strength and fatigue. Physiotherapy 1977;**63**(2):51-5

12. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respiratory medicine 1991;**85 Suppl B**:25-31; discussion 33-7

13. British Thoracic Society's current guidance: Recommendations of the BTS & ARTP. Guidelines for the measurement of respiratory function. Respiratory Medicine 1994;**88**:165-94

14. Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992;**47**(12):1019-24

15. Revill SM, Morgan MD, Singh SJ, et al. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999;**54**(3):213-22

16. Watson EL, Greening NJ, Viana JL, et al. Progressive Resistance Exercise Training in CKD: A Feasibility Study. American journal of kidney diseases : the official journal of the National Kidney Foundation 2014 doi: 10.1053/j.ajkd.2014.10.019[published Online First: Epub Date]|.

17. Shrikrishna D, Patel M, Tanner RJ, et al. Quadriceps wasting and physical inactivity in patients with COPD. The European respiratory journal 2012;**40**(5):1115-22 doi: 10.1183/09031936.00170111[published Online First: Epub Date]|.

18. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. The European respiratory journal 2010;**36**(1):81-8 doi: 10.1183/09031936.00104909[published Online First: Epub Date]|.

19. Kon SS, Canavan JL, Nolan CM, et al. The 4-metre gait speed in COPD: responsiveness and minimal clinically important difference. The European respiratory journal 2014;**43**(5):1298-305 doi: 10.1183/09031936.00088113[published Online First: Epub Date]|.

20. Kortebein P, Ferrando A, Lombeida J, et al. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA : the journal of the American Medical Association 2007;**297**(16):1772-4 doi: 10.1001/jama.297.16.1772-b[published Online First: Epub Date]|.

21. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003;**58**(9):752-6

22. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000;**355**(9201):362-8

23. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006;**61**(9):772-8 doi: 10.1136/thx.2006.060145[published Online First: Epub Date]|.

24. Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. Chest 2006;**129**(3):536-44 doi: 10.1378/chest.129.3.536[published Online First: Epub Date]|.

25. Jones SE, Green SA, Clark AL, et al. Pulmonary rehabilitation following hospitalisation for acute exacerbation of COPD: referrals, uptake and adherence. Thorax 2014;**69**(2):181-2 doi: 10.1136/thoraxjnl-2013-204227[published Online First: Epub Date]|.

26. Benzo R, Wetzstein M, Neuenfeldt P, et al. Implementation of physical activity programs after COPD hospitalizations: Lessons from a randomized study. Chronic respiratory disease 2015;**12**(1):5-10 doi: 10.1177/1479972314562208[published Online First: Epub Date]|.

27. Greening NJ. Non-adherence to peri-exacerbation pulmonary rehabilitation: the people have spoken. Chronic respiratory disease 2015;**12**(1):3-4 doi: 10.1177/1479972314565360[published Online First: Epub Date]|.

28. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. The European respiratory journal 2014;**44**(6):1428-46 doi: 10.1183/09031936.00150314[published Online First: Epub Date]|.

29. Hill K, Dolmage TE, Woon L, et al. Comparing peak and submaximal cardiorespiratory responses during field walking tests with incremental cycle ergometry in COPD. Respirology 2012;**17**(2):278-84 doi: 10.1111/j.1440-1843.2011.02089.x[published Online First: Epub Date]|.

Funding

The research was funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care in Leicestershire, Northamptonshire and Rutland (CLAHRC LNR). Support was also provided by the NIHR Leicester Respiratory Biomedical Research Unit.  The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

***Table 1****: Clinical characteristics of the subjects at time of recruitment (unscheduled hospitalisation, n=191)*

|  |  |  |
| --- | --- | --- |
| Variable | Mean | SD |
| Age (years) | 71.6 | 9.1 |
| BMI (kg/m2) | 26.0 | 6.0 |
| Gender (% Male) | 45.6% |  |
| MRC grade when stable (median) | 4 | IQR 1 |
| Smoking (% current) | 22.1% |  |
| Pack years (years) | 46.0 | 35.9 |
| Home oxygen use (%) | 28.3% |  |
| Number of co-morbidities (median) | 2 | IQR 2 |
| Hospitalised in previous year (% yes) | 52.4% |  |
| Co-habitation (% living alone) | 38.6% |  |
| Principal Diagnosis |  |  |
| COPD | 80.6% |  |
| Chronic asthma | 6.8% |  |
| Interstitial lung disease | 5.8% |  |
| Bronchiectasis | 6.8% |  |
| SGRQ Symptoms | 76.59 | 18.14 |
| SGRQ Activity | 87.16 | 11.77 |
| SGRQ Impact | 57.95 | 18.51 |
| SGRQ Total | 70.06 | 14.01 |
| Quadriceps strength (kg) | 15.5 | 7.1 |
| Quadriceps Cross sectional area (cm2) | 4.76 | 1.41 |
| Heart rate (bpm) | 85.9 | 17.8 |
| Incremental shuttle walk test (m) | 109 | 86 |
| Endurance shuttle walk test (s) | 112 | IQR 144 |
| FEV1 on discharge (L) | 0.97 | 0.44 |
| FEV1 % predicted (%) | 44 | 19 |
| FEV1/FVC (%) | 53 | 15 |
| Medication |  |  |
| Long acting muscarinic antagonist | 52% |  |
| Long acting beta agonist | 56% |  |
| Inhaled corticosteroid | 77% |  |
| Long term oral steroids | 14% |  |

SGRQ: St George’s Respiratory Questionnaire, FEV1: Forced expiratory volume in one second

***Table 2:*** *Factors associated with re-hospitalisation or death at one year in the univariate analysis. Odds ratios (OR) are shown for each separate variable. Significant variables are shown in bold. Odds ratios are per unit increase for continuous variables. For categorical variables the group for which the OR is shown is provided in the bracket.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | OR | 95% CI | 95% CI | p |
| **Age** | **1.05** | **1.01** | **1.08** | **0.015** |
| Gender (female) | 0.67 | 0.35 | 1.28 | 0.226 |
| BMI | 0.96 | 0.91 | 1.02 | 0.164 |
| Lives with (spouse) | 0.56 | 0.27 | 1.16 | 0.118 |
| **MRC dyspnoea score** | **4.57** | **2.62** | **7.95** | **<0.001** |
| Main diagnosis (ILD) | 1.47 | 0.36 | 6.03 | 0.589 |
| Smoking (yes) | 0.46 | 0.11 | 1.87 | 0.280 |
| Pack years | 1.00 | 0.99 | 1.01 | 0.608 |
| **Long term oxygen therapy (yes)** | **12.4** | **4.53** | **33.77** | **<0.001** |
| Quadriceps strength | 0.96 | 0.92 | 1.01 | 0.124 |
| **Qcsa** | **0.34** | **0.17** | **0.65** | **0.001** |
| ISWT | 1.00 | 0.99 | 1.00 | 0.077 |
| ESWT | 1.00 | 1.00 | 1.00 | 0.210 |
| FEV1 on discharge | 0.49 | 0.23 | 1.05 | 0.066 |
| Total number of co-morbidities | 0.87 | 0.69 | 1.12 | 0.282 |
| Mobility limiting comorbidity\* (yes) | 0.69 | 0.36 | 1.32 | 0.263 |
| Initial length of hospital stay | 1.06 | 0.99 | 1.14 | 0.092 |
| **Previous hospitalisation (yes)** | **4.82** | **2.42** | **9.58** | **<0.001** |
| Treatment allocation (intervention) | 1.31 | 0.69 | 2.49 | 0.416 |

ILD: interstitial lung disease, Qcsa: Quadriceps cross sectional area over height squared, ISWT: Incremental shuttle walk test, ESWT: endurance shuttle walk test, FEV1: Forced expiratory volume in one second, Hospitalisation in previous 12 months, \*defined as significant cardiac disease, musculo-skeletal disease or vascular disease

***Table 3:*** *Multivariate analysis of variables significantly predictive of hospitalisation or death in the 12 months following measurement. Odds ratios are per unit increase for continuous variables. For categorical variables the group for which the OR is shown is provided in the bracket.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | OR | 95% CI | | p |
| Long term oxygen therapy (yes) | 4.80 | 1.68 | 13.69 | 0.003 |
| MRC Dyspnoea Grade | 2.57 | 1.44 | 4.59 | 0.001 |
| Admitted in previous year (yes) | 3.04 | 1.47 | 6.29 | 0.003 |
| Quadriceps cross sectional area | 0.46 | 0.22 | 0.95 | 0.035 |

***Table 4:*** *Comparison of clinical characteristics of the smaller muscle (Qcsa<4.79cm2) and larger muscle groups (Qcsa ≥4.79cm2). Significant differences are shown in bold.*

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variable | Quartile 1  (Smallest)  n=47 | | Quartile 2  N=48 | | Quartile 3  N=48 | | Quartile 4  (Largest)  n=48 | | p |
|  | Mean | SD | Mean | SD | Mean | SD | Mean | SD |  |
| Age (years) | 73 | 9 | 72 | 10 | 71 | 9 | 70 | 8 | 0.287 |
| **Weight (kg)** | **63.6** | **16.8** | **65.1** | **16.6** | **74.2** | **15.3** | **77.3** | **17.9** | **<0.001** |
| **BMI (kg/m2)** | **22.7** | **4.6** | **24.8** | **5.4** | **27.6** | **5.5** | **28.8** | **6.4** | **<0.001** |
| **QMVC (kg)** | **12.6** | **7.1** | **13.9** | **5.7** | **18.1** | **7.7** | **17.1** | **6.6** | **<0.001** |
| ISWT (m) | 109 | 86 | 100 | 91 | 119 | 85 | 110 | 83 | 0.815 |
| ESWT (s) | 103 | 82 | 133 | 202 | 127 | 97 | 131 | 99 | 0.725 |
| Oxygen Saturations (%) | 93 | 4 | 93 | 3 | 92 | 4 | 93 | 3 | 0.908 |
| Heart Rate (bpm) | 87 | 16 | 89 | 14 | 89 | 11 | 92 | 14 | 0.261 |
| FEV1(L) | 0.90 | 0.39 | 0.86 | 0.39 | 1.03 | 0.40 | 1.09 | 0.54 | 0.060 |
| FEV1(% predicted) | 41 | 19 | 44 | 19 | 46 | 17 | 47 | 21 | 0.441 |
| MRC dyspnoea grade | 4 | 0 | 4 | 1 | 4 | 1 | 4 | 1 | 0.281 |
| Number of co-morbidities | 3 | 2 | 2 | 2 | 2 | 1.5 | 2 | 2 | 0.148 |
| Index length of hospital stay | 7 | 7 | 5 | 6.5 | 6 | 5 | 5 | 5 | 0.070 |
| Gender (% male) | 49% | | 40% | | 44% | | 50% | | 0.717 |
| Lives with (% alone) | 46% | | 40% | | 47% | | 23% | | 0.158 |
| Principal diagnosis (% COPD) | 74% | | 85% | | 88% | | 75% | | 0.541 |
| Admitted in previous year | 66% | | 50% | | 48% | | 46% | | 0.188 |
| Admitted ≥2 in previous year | 32% | | 29% | | 19% | | 17% | | 0.217 |
| Mobility limiting co-morbidity (%yes) | 51% | | 35% | | 50% | | 29% | | 0.074 |

**List of Figures**

***Figure 1****: Cox regression curve of risk of hospitalisation or death for quartiles of different quadriceps muscle size. Covariates in the model are hospitalisation in the previous year, MRC dyspnoea grade and home oxygen use. Significant difference is present between smallest and largest muscle groups at 12 months (p=0.007).*

***Figure 2:*** *Mean number of days spent in hospital in the year following the index admission. Groups shown are quartiles of quadriceps size, measured using ultrasound and corrected for patients’ height. Error bars are 95% poisson confidence intervals.*